Lung CancerULYSSENCT05267041
Joint Thoracic Oncology Research Unit of LYon: Lung cancerS DatabaSE (ULYSSE)
A study testing Blood sample and Questionnaire in people with Lung Cancer, run by Hospices Civils de Lyon at 1 site in France.
Trial summary
Prospective longitudinal cohort associated to blood collection, pathological samples collection, and radiological and pathological imaging collection. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancer
- What is being tested?
- Blood sample and Questionnaire
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4,000 participants
- Where
- 1 siteFrance
- Study dates
- 5 May 2022to 5 May 2042
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient treated for a thoracic cancer in the Lyon University Hospital: non-small cell lung cancer, small cell lung cancer, mesothelioma…
- Diagnosis can be done:
- By cytology or pathologic assessment
- Or by multidisciplinary team meeting decision:
- Irradiation without morpho-metabolic sampling
- Treatment without sampling based on non-invasive molecular data
Who cannot join
- Refusal to participate
- For optional blood sampling :
- < 30 kg for blood collection
- No blood sampling schedule for care
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495
Sébastien COURAUD, PhD, 0478863718 ext. +33, sebastien.couraud@chu-lyon.fr
About this study
Official title: Prospective Longitudinal Cohort Associated to Blood Collection, Pathological Samples Collection, and Radiological and Pathological Imaging Collection
Prospective longitudinal cohort associated to blood collection, pathological samples collection, and radiological and pathological imaging collection.
- Conditions
- Lung Cancer
- Being tested
- Blood sample, Questionnaire
- Keywords
- Data collection, lung cancer
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood sampleBiological
One optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer
QuestionnaireOther
to collect data not reported in the patient's medical file, such as passive smoking, family history of cancer, and attempts to quit smoking.
| Study group | Role | What they receive |
|---|---|---|
| Cohort of Adults with lung cancer | Experimental | Patients newly diagnosed with lung cancer. Receives: Biological: Blood sample; Other: Questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants registered in the lung cancer database
cohort open to recruitment during 10 years with 10 years of patients follow-up
Measured: 20 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2022
- Study start5 May 2022
- Primary completion5 May 2032 (estimated)
- Study completion5 May 2042 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- One questionnaire between diagnostic annoucement and first line treatement One 6 months later One before second line treatment One 6 months later after second line treatment Optionnal Veinous Blood Sample (28 mL) between the diagnostic annoucement and the first line of treatment
- Masking
- None (open label)
- Enrolment
- 4,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05267041
- Sponsor's protocol ID
- 69HCL21_1175
- Acronym
- ULYSSE
- Status last verified
- Nov 2025
- First submitted
- 14 Feb 2022
- Last updated
- 21 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Longitudinal Cohort Associated to Blood Collection, Pathological Samples Collection, and Radiological and Pathological Imaging Collection
- ClinicalTrials.gov ID
- NCT05267041
- Acronym / sponsor ID
- ULYSSE / 69HCL21_1175
- Conditions
- Lung Cancer
- Keywords
- Data collection, lung cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 4,000 participants (estimated)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 5 May 2022 (actual)
- Primary completion
- 5 May 2032 (estimated)
- Study completion
- 5 May 2042 (estimated)
- First posted
- 4 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prospective longitudinal cohort associated to blood collection, pathological samples collection, and radiological and pathological imaging collection.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- One questionnaire between diagnostic annoucement and first line treatement One 6 months later One before second line treatment One 6 months later after second line treatment Optionnal Veinous Blood Sample (28 mL) between the diagnostic annoucement and the first line of treatment
| Arm | Type | Receives |
|---|---|---|
| Cohort of Adults with lung cancer | Experimental | Biological: Blood sample, Other: QuestionnairePatients newly diagnosed with lung cancer. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Patient treated for a thoracic cancer in the Lyon University Hospital: non-small cell lung cancer, small cell lung cancer, mesothelioma…
- Diagnosis can be done:
Key exclusion criteria (4 listed)
- Refusal to participate
- < 30 kg for blood collection
- No blood sampling schedule for care
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood sampleOne optional veinous blood sampling (24 ML) between the first diagnostic annoucement and before the first treatment for lung cancer | Biological | Cohort of Adults with lung cancer |
| Questionnaireto collect data not reported in the patient's medical file, such as passive smoking, family history of cancer, and attempts to quit smoking. | Other | Cohort of Adults with lung cancer |
Primary outcome
Number of participants registered in the lung cancer database
Time frame: 20 years
cohort open to recruitment during 10 years with 10 years of patients follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2025.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blood sample and Questionnaire in people with Lung Cancer, run by Hospices Civils de Lyon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants registered in the lung cancer database (time frame: 20 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2025.